Clearside Biomedical to Report Third Quarter 2023 Financial Results and Provide Corporate Update on Monday, November 13, 2023
31 oct. 2023 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical Announces Second Quarter 2023 Financial Results and Provides Corporate Update
14 août 2023 16h05 HE
|
Clearside Biomedical, Inc.
- Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Progressing as Planned with Nearly 30 Sites Now Open - - Proprietary Suprachoroidal Injection Platform Featured in Peer-Reviewed Publication and at ARVO,...
Clearside Biomedical’s Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings
20 juil. 2023 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., July 20, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Global Nonmydriatic Handheld Fundus Cameras Strategic Business Report 2023: Rise of AI-Powered Non-Mydriatic Handheld Devices Drives Growth
19 juil. 2023 04h28 HE
|
Research and Markets
Dublin, July 19, 2023 (GLOBE NEWSWIRE) -- The "Nonmydriatic Handheld Fundus Cameras: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market...
Clearside Biomedical Announces Enrollment of Multiple Participants in its ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD
17 juil. 2023 07h05 HE
|
Clearside Biomedical, Inc.
- Evaluating CLS-AX as a Potential Twice-a-Year Therapy - - Trial Progressing with Topline Results Expected in Q3 2024 - ALPHARETTA, Ga., July 17, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical,...
Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema
10 juil. 2023 07h05 HE
|
Clearside Biomedical, Inc.
- XIPERE® is referred to as Arcatus (ARVN001) by Arctic Vision – ALPHARETTA, Ga., July 10, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company...
AI-Based Health Screening Company iHealthScreen Reaches $150K in Investments
26 juin 2023 20h25 HE
|
iHealthScreen Inc.
RICHMOND HILL, N.Y., June 26, 2023 (GLOBE NEWSWIRE) -- AI-based health screening company iHealthScreen recently announced raising $150,000 in investments on StartEngine. To date, the company has...
Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD
01 juin 2023 07h05 HE
|
Clearside Biomedical, Inc.
- U.S. Clinical Sites Screening Treatment-Experienced Participants with Wet AMD - - ODYSSEY Topline Results Expected in Q3 2024 - ALPHARETTA, Ga., June 01, 2023 (GLOBE NEWSWIRE) --...
Clearside Biomedical to Participate in a Fireside Chat at the JMP Securities Life Sciences Conference
09 mai 2023 16h30 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., May 09, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Global Macular Degeneration Treatment Market Report 2023: Major Players Include Novartis, Bausch Health Companies, Regenxbio, F Hoffmann-La Roche and Regeneron Pharmaceuticals
23 mars 2023 11h03 HE
|
Research and Markets
Dublin, March 23, 2023 (GLOBE NEWSWIRE) -- The "Macular Degeneration Treatment Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides...